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Abstract 
Our increasing understanding of the molecular pathology of disease, particularly through genomic 
studies, has created significant opportunities for the development of therapeutics that specifically 
target discrete molecular subclasses, but equally, has generated substantial challenges in how to 
develop and implement these strategies. Variously termed personalised, stratified, individualised or 
precision medicine, the approach is centered on delivering the optimal therapy for an individual 
based on specific clinical and molecular features of their disease. The development of new 
therapeutics that target molecular mechanisms has driven considerable change and innovation in 
clinical trial strategies. We have made progress through improved efficiency and changes in clinical 
trial design, yet continued innovation through the modification of existing core paradigms in 
oncology drug development and clinical care are required to fully realise the promise of precision 
medicine. 
 
Introduction 
Insights into the molecular pathology of disease are creating opportunities for more durable clinical 
benefit, but are also challenging the existing paradigm of therapeutic development and clinical care 
1-3. Large international consortia such as the International Cancer Genome Consortium 4,5 are 
mapping thousands of cancer genomes to identify opportunities for prevention, early detection and 
treatment 6. Although genomics is leading the way, high throughput proteomics and metabolomics 
are following closely behind 7. Such advances have ushered in a new era of therapeutics that 
target specific molecular processes. Although we have had some dramatic successes 8-17, the 
overall strategy remains in its infancy 18. The central premise of precision medicine is that by 
matching a drug and its mechanism of action to select patients we can offer greater potential for 
durable clinical benefit - often referred to as “matching the right drug to the right patient”. 
Initially, targeted agents followed much the same clinical development pathway as cytotoxic 
chemotherapy based on tumour location and histopathology; driven by the then notion that 
molecular aberrations were tumour specific. A lack of efficacy data in patients with different cancer 
types harbouring a shared molecular aberration, coupled with early observations that the functional 
significance of (some) aberrations varied between tumour types, stalled efforts to advance these 
approaches. However, the subsequent emergence of programmes that identified molecular targets 
and matched treatment to molecular subtype led to several reports (M.D. Anderson Cancer Centre 
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19; MOSCATO study 20) which directly linked this approach to improvements in clinical outcome, 
irrespective of the organ of origin. Although the data were based on retrospective analysis of 
tumour samples, and not all reports equally as convincing 21, the utility of broad molecular profiling 
to guide patients to specific targeted therapies had been established. Researchers moved quickly 
to implement this new paradigm. In turn, established pathways of therapeutic development would 
need to change to meet these emerging requirements, and although the practical implications of 
clinical implementation were less clear, the promise of clinical benefit was enticing... 
The drivers for precision medicine are established and robustly discussed elsewhere 18,22,23, 
however, the new challenges for therapeutic development are many and substantial: 
Fundamentally, a candidate  therapeutic strategy requires a strong platform of evidence to support 
clinical testing coupled with robust methods to define the right patients (using molecular assays 24). 
Our appreciation of molecular diversity of cancer and the ever-increasing number of molecular 
subgroups (segments) creates significant complexity for targeted drug development. When tested 
in trials of unselected participants, most targeted therapies reveal efficacy only when both the 
incidence of a responsive sub-population and the effect size in this group is sufficiently high. 
Increasing the size of clinical trials to overcome this lack of enrichment yields minimal overall 
benefits at a cost that makes them unattractive and unaffordable to the community. Trials that 
feasibly evaluate both patient selection and drug efficacy are key, and it is essential to define the 
correct metrics, particularly with the smaller studies that are required. 
 
Principles and evolution of clinical trials 
Clinical trials are most useful when it is important to assess a potential therapeutic effect that is 
about the same size or smaller than natural person-to-person variability. When subject variation 
influences a treatment only randomly, it can be ignored in a biological sense and controlled by 
replication. These dual strategies for controlling variation embody the empiric and theoretical 
aspects of trials. For much of the history of clinical trials, the treatments under investigation have 
been assumed, correctly or not, to apply to anyone with the relevant clinically defined condition; i.e. 
our understanding of biology suggested treatments worked through common mechanisms apart 
from random variation. This assumption was substantially correct for therapeutics that targeted 
more generic mechanisms such as cytotoxic chemotherapy, and enabled significant progress 
against cancer to be made. Towards the end of the 20th century, concerns arose regarding 
potential inhomogeneity of therapeutic effects based on socio-political characteristics such as race 
or sex, with many clinical trials designed and analysed to examine such differences. Although the 
motives were based on politics and social justice rather than science, the trial designs employed 
were little changed, which was likely appropriate given the weak biological basis for differences 
attributed to these superficial characteristics. 
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The recognition of non-random variation that demands altered clinical trial design has come more 
from knowledge of the disrupted cancer genome rather than the germ line. The implications of 
having multiple potential treatments and diseases where a single one once stood creates 
enormous pressure to alter study design – and many investigators approach the challenges of too 
many diseases and too few subjects created by genomic partitioning of cancer as a clinical trial 
design problem. This can create unhealthy tension because although new designs must follow new 
questions, many of the questions of targeted therapies are actually standard, and well-established 
methodologies remain appropriate. Consequently, the challenges of clinical testing of most 
precision medicine strategies revolve around feasibility, efficiency and adaptability to deal with 
multiple small incidence subtypes and a rapidly evolving knowledge base. 
Staging of drug development evolved to accommodate the 2 strategies required: generating strong 
safety and efficacy signals for effective treatments, and terminate development of ineffective ones 
as early as possible. In broad terms: 1) Early development (phase I) focuses on dosing and safety; 
2) middle development (phase II) examines a larger group of patients to further evaluate safety and 
efficacy for a critical go-no-go decision; 3) Late development (phase III) constitutes definitive 
comparative testing and provides a basis to seek market approval. Phase IV studies are 
sometimes performed following market approval to examine additional patient populations, side 
effects, long term use, and to potentially extend indications. Iterative building of evidence either 
supports or refutes the use of the new therapeutic for a specific indication. In this paradigm a 
premium is placed on randomised, controlled designs. 
The strategy of biomarker driven patient selection (enrichment) is well established for high 
prevalence biomarkers and is either based on retrospective analysis of randomised controlled 
trials; biomarker discovery integrated within the design to ensure sufficient power to detect signals; 
and equal distribution of marker positive patients in each arm (confusingly termed biomarker 
stratification); and biomarker directed studies (Figure 1) 25-27. However, advances in our 
understanding of differences in the molecular pathology of individual cancers raises inevitable 
challenges around typical development paradigms as the prevalence of molecular segments 
decreases 28.  For example; if the incidence of a marker that identifies tumours most likely to 
respond to a targeted therapeutic is only ~2% (a typical prevalence for many if not most molecular 
subgroups), then the chances of a successful outcome in a traditional comparative trial are 
diminishing small 29. Two percent of patients yields only 1-2 patients in a 50-100 patient study. No 
level of clinical effect in such few patients would be sufficient to advance therapeutic development, 
assuming there is no clinical effect in the marker negative population. 
Evaluating a new targeted drug or treatment in the early phases of development requires a trial 
that minimises the inclusion of patients unlikely to respond for mechanistic reasons, i.e. a selected 
patient population. This inevitability yields smaller trial sizes, smaller data packages for making 
decisions on trial phase transitions, and challenges in developing appropriate comparator 
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populations in earlier studies. The questions such approaches raise are how many patients are 
required to be evaluated to truly understand the safety and efficacy of the drug or treatment; should 
later clinical phase studies remain focused solely on the selected patient population and use single 
arm studies; what are the drug effects in marker negative patients (which will happen in routine 
clinical practice due to diagnostic inaccuracies even if such patient populations are not investigated 
during development); how we build the body of evidence needed to support the approved use of a 
drug or therapeutic in a particular indication. As a consequence, the entire development pathway 
becomes challenged – from the basic practicalities of how to find sufficient patients selected by low 
incidence markers to investigate and how to understand the utility of the markers used for 
selection, through to central aspects of the development pathway such as how to generate the 
data packages needed for regulatory submissions and market approval.  
 
The emerging model of patient-centric drug development 
The challenges above have produced umbrella and basket trials. Umbrella studies are within 
tumour types, selected by different markers for single/multiple candidate drugs, and basket studies 
are across tumour types, often selected by a single marker or for a single candidate drug (figure 2).  
An umbrella study typically investigates a single tumour type, for example lung cancer, and has 
patients directed to different arms of the study and hence different therapeutics based on their 
tumour’s molecular characteristics. A basket study also uses selection based on tumour molecular 
characteristics and selection markers but irrespective of tumour type and is often focused on one, 
(or a few) specific markers. The choice of approach is based on various aspects from the relative 
prevalence of the molecular subgroup within versus across different cancer types (figure 2), 
initiatives of tumour-specific cooperative groups, or the simple practicalities of implementing these 
studies such as the ability to acquire tumour material for analysis. 
One solution to some of the challenges in development discussed above is the use of Master 
Protocols, some of which have been established for efficiency in certain settings (figure 3)(table 1). 
Rather than using serial, single diagnostics to select participants for different trials, a single 
multiplex diagnostic assay is often used to assign participants to different candidate drugs (or trial 
arms) within the same trial, or a networked trial architecture. Some refer to this as a “tent” protocol, 
where multiple trials through various mechanisms are available. Such studies offer greater options 
for patients with potential for significant efficiencies for screening and trial recruitment.  
Increasingly, adaptive trial design features are incorporated. These differ from many traditional 
designs by using accumulating results to modify the trial course or structure. The ability to make an 
early assessment of clinical benefit (or safety) and to modify the trial subsequently allows for a 
nimble approach. Advantages are: 1) the decision to stop early or extend accrual based on 
emerging results, 2) dropping arms or doses if no benefit is seen, 3) finding responder populations, 
or combinations of markers and drugs/therapeutics, 4) changing randomisation proportions, 5) 
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changing accrual rates, and 6) allowing multiple stages of development to be included in a single 
trial. Such staged approaches can significantly enable the drug development process (figure 4). 
Examples of trials using these approaches include the BATTLE 30 and I-SPY series 31-35 of trials for 
lung and breast cancer. 
Oncology drug development is now evolving rapidly, with notable expansions of precision medicine 
programmes in recent years (table 1). The understanding of the molecular pathology of tumours in 
unprecedented detail coupled with modern drugs and associated diagnostic technologies to select 
patients has enabled tangible improvements in survival rates in some cancer types 10-17; 
particularly exemplified in patients with Non Small Cell Lung Cancer (NSCLC) 13,16. More recently, 
significant durable responses to immune modulatory therapies are emerging in ~15% of patients. 
These agents mostly target specific molecular mechanisms, which are currently the focus of 
intense investigation. It is likely that patient selection will also play a significant role in the 
development of these agents, with biomarker hypotheses actively being developed 36. Data are 
beginning to emerge from early programmes such as SHIVA 37, which broadly evaluated targeted 
therapies using a histology agnostic approach in end stage patients who failed standard therapy. 
Although no difference was identified 38, it is not possible to draw broad conclusions, exemplifying 
the challenges ahead.  
The oncology landscape continues to evolve towards an increasing number of patient/tumour 
groups39 identified by (increasingly complex) diagnostic assays to enable coupling to molecular 
targeted drugs. (For additional information and up-to-date approvals, see U.S. Food and Drug 
Administration (FDA) 40-42 and the European Medicines Agency (EMA) 43). Whilst most approved 
therapies have a linear relationship with a single marker, emerging data suggest that combinations 
of markers or different readouts may better inform therapeutic responsiveness, and will continue to 
challenge biomarker development strategies. Similarly, multiple markers may confer sensitivity to a 
single therapeutic, and a single marker may offer several therapeutic options. Such overlaps are 
inevitable and defining appropriate measures on how to respond during the drug development 
process are important. The emerging complexity is posing substantial challenges to current 
regulatory processes. How are therapies independent of organ of origin assessed, particularly 
when the prevalence is low in an organ type? How do we deal with therapies at different stages of 
the disease with several prior treatments? Perhaps we could look to broader approaches, such as 
reimbursement defined for a particular disease stage and line of treatment, with decisions on 
choice of therapy made between clinicians and their patients. 
 
Overcoming the challenges of early drug development 
Clinical testing in early development poorly predicts efficacy in late development 24,44. If this were 
not the case, late development would be unnecessary. Bias in small early trials can raise 
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expectations, only to disappoint when expanded to larger, less selected and “unbiased” 
populations. We now have the tools to better understand the molecular pathology of tumours to 
inform smaller trials, and importantly define sources of bias at a molecular level to inform early and 
on-going therapeutic development. An emerging approach is testing small numbers of patients 
underpinned by a deep understanding of the molecular composition of tumours and the 
mechanism of action of the therapeutic, with knowledge acquired through clinical testing informing 
ongoing pre-clinical strategies, which in turn further refine the clinical testing approach (backward 
and forward translation)(figure 5). 
Inherent to the latter approach is the desire to define more effective therapies and set the bar 
higher for progression of the therapeutic down the development path. With the multitude of 
emerging potential therapies and molecular subgroups, we need to move from a high investment 
drug development approach with a dominance of late phase failures, to one that “fails early” and 
“fails cheaply” so that more potential therapies can be assessed and costs be constrained; and 
perhaps bolder biological hypotheses could be reasonably tested. With these tools in hand, and 
developing rapidly, the challenge becomes how, or if we can implement these in the real world. 
Whilst parallelised master protocol clinical trials using umbrella and basket designs create 
efficiencies, the subdivision of tumour/therapeutic pairs continues to push for more innovative 
solutions and approaches, particularly in early drug development 27,45. There may simply not be 
enough patients to test the therapeutic based on traditional approaches. Figure 6 shows a 
suggested strategy for the therapeutic development of a cancer type with an overall population 
incidence of 10 per 100,000 per annum. Supportive evidence for a particular strategy is classified 
based on an “Actionability Index”. Approaches for each therapeutic may progress within this 
framework, or to pivotal studies when there is sufficient evidence to do so. 
 
Accelerating stratified therapeutic development – overcoming operational challenges 
Precision therapeutic development focuses around leveraging the science, but many key 
challenges pivot around operational components46. These require integration of multiple complex 
processes such as 1) participant screening and recruitment; 2) molecular testing; 3) protocol 
flexibility; and 4) availability and delivery of therapies (Table 2) . 
Participant screening and recruitment: The realities of conventional screening approaches for 
clinical drug development are sobering. For a study testing a new candidate drug in a patient sub-
population selected by a molecular marker with a 2% incidence, with indicative rates of screening 
failure (for technical reasons; 15%) and patient drop-out (for clinical reasons; 15%), the trial would 
need to screen 78 patients to find 1 patient for recruitment, and 77 patients would effectively be 
discarded. The costs are equally sobering: if screening uses (even just) an existing routine single 
variable diagnostic approach such as immunohistochemistry (IHC) or a single gene DNA test, each 
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with an approximate cost of $1,125 US/assay (including assay, processing, logistics and reporting), 
it would cost $88,235 to screen sufficient numbers to recruit 1 patient to the study. Putting this in 
context; if we wanted to conduct a 20 patient phase I expansion study in this selected patient sub-
population, it would require screening some 1,560 patients, with an associated screening cost of 
$1.8 million US.  
The patient experience is also extremely poor with cycles of disappointment; being first considered 
for a trial, only then to be ineligible if the marker is not present; the necessity of repeat biopsies for 
the next marker, and ultimately limited drug options (only those for which a “serial” screen has 
been possible). The physician experience is similarly poor with limited options other than to keep 
screening for different markers, and trials, as long as tumour material is available. From a clinical 
trial operational viewpoint, this is unsustainable.	  
The need to find sufficient numbers of patients with a specific marker has generated many co-
operative study groups (table 1b). Consortia provide multiplexed molecular testing (measuring 
many markers in one assay) for recruitment as part of the drug development process, as well as 
programmes that offer “self-tested” patients access to appropriate therapy either as part of clinical 
trials or “off label” treatment. Such examples include national-level, cross-sector collaborative 
(including government-based) initiatives such as the NCI-MATCH 47 (for solid tumours) and Lung-
MAP 48 (in squamous lung cancer, NCT02154490) programmes in the USA; the SPECTA 
programmes (SPECTAcolor 49 in colorectal cancer, NCT01723969; SPECTALung 50 in lung 
cancer; NCT02214134) and the AURORA initiative in Europe 51 (breast cancer, NCT02102165); 
the LC_SCRUM (and SCRUM-Japan) programmes 52 in Japan; or those lead by cancer specific 
advocacy and charity organisations eg: The “Know Your Tumour” programme established by the 
Pancreatic Cancer Action Network in the United States 53. These models are advancing precision 
oncology, yet are costly, requiring intermediaries to navigate the patient through the health system. 
They will be difficult to scale without fundamental changes in health service delivery. Some 
emerging approaches are driven by the patient and their clinician. These include clinical trials and 
other therapeutic options as part of a molecular assay report e.g. Foundation ONE® from 
Foundation Medicine 54; and connections  to further information, consumer-focused advice, 
community and patient consortia 55. These approaches cast a broader net to identify smaller and 
smaller subgroups and identify opportunities for individual patients. More recently, strategies that 
provide genomic health advice 56 and navigation are gaining traction e.g. Perthera 57. Others are 
looking towards electronic media to enable patients and their clinicians to “shop around” for the 
best option for them. These strategies can significantly improve efficiency and the patient 
experience. Despite these efforts, trials using a selection marker constitute still only a minority of 
studies currently underway 58. 
A major challenge, once an eligible patient is found is recruiting them onto trial. With the low 
prevalence of eligible patients, large numbers of sites may need to be opened, at significant cost, 
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and many may not recruit a single patient. As screening programmes develop, the cost of finding 
patients shifts from drug developers to health care systems or research platforms. A possible 
solution is to open trials at a site that is feasible for the patient once they have been identified. This 
represents a type of “just-in-time” accessibility. The cost of having rapidly deployable teams to 
establish sites once a patient is found is likely to be less than screening large numbers of patients. 
 
Molecular Testing: While multiplex testing of the coding regions of candidate genes offers some 
options, the complexity of cancer will require more in depth analyses 59. The challenges of 
delivering molecular assays using advanced technologies are well discussed elsewhere 59, 
however current tests exploit relatively direct relationships between a specific mutation and drug 
efficacy. Appraising and delivering more complex assays that may better identify responsive 
subgroups 60,61 is proving difficult despite advances in clinical grade diagnostics 62 mainly due to 
the rigidity and inertia of entrenched processes for biospecimen handling. Simpler solutions such 
as liquid biopsies 63,64 are promising, but may lack broad applicability, particularly when complex 
molecular changes need to be analysed. Technology considerations aside, it is more important to 
understand the relevance of detected changes/mutations and the body of evidence required to 
substantiate their use for patient selection. Modern multiplex systems such as next generation 
sequencing (NGS) technologies reveal unprecedented levels of detail of the molecular changes 
within a single tumour, many of which may not have been widely reported; some of which are likely 
to be individual to that tumour (or tumour region), and for most there may be little prior clinical 
experience or knowledge.  How then, do we understand which should inform therapeutic selection?  
Whilst specific mutations in a particular gene may confer sensitivity to a particular therapeutic, what 
decision do we make if we find different mutations not previously reported in that gene: can we 
reasonably expect these to similarly confer therapeutic sensitivity? This is a challenge for trial 
design and the diagnostic algorithm used to assign patients to treatment. We need to guard 
against reporting a study as negative based on a lack of clinical benefit seen in a subpopulation 
defined by mutations of unknown consequence. Although some mutations in a gene may be 
predictive of clinical benefit, others may not, so we need to accommodate these unknowns.  
Practical solutions may combine adaptations as above with basket or umbrella trial arms that can 
examine combinations of markers and therapeutics in isolation, along with diagnostic mutation 
tiering where mutations of known clinical or functional consequence are weighted differently to 
those of unknown consequence. 
Protocol Flexibility: The administrative aspects and logistical challenges of clinical trials are 
substantial and impede the ability to nimbly respond to trial findings, particularly if unexpected, or 
data emerge from elsewhere. Establishing frameworks and platforms for stratified therapeutic 
development will allow standardisation of within protocol responses to specific scenarios to 
improve flexibility (table 2) 
9	  
	  
Availability and Delivery of Therapeutics: Molecular analysis without the prospect of a resulting 
action is of little benefit. There are still comparatively few opportunities in routine care where 
multiplexed testing can influence clinical decision-making and  access to appropriate therapeutics 
is still problematic 65. Negotiating individual clinical trials “ad-hoc” is impractical due to slow legal 
and administrative processes, and a closer relationship between the pharmaceutical industry and 
other stakeholders is essential. The collective involvement of multiple pharmaceutical partners to 
allow availability of a broader range of candidate drugs and appropriate comparator therapies; and 
wider collaboration between tumour-specific consortia, diagnostic and regulatory groups; major 
charities and other interested parties will be pivotal. A drug portfolio approach is a necessity, which 
is negotiated as a broad partnership or through a consortium strategy, and the ability to feasibly 
deliver the therapeutic through systems such as a centralised pharmacy are essential. The ability 
to offer patients and their clinicians a broad selection of attractive opportunities, where each patient 
has a real option, will enhance participation in clinical trials, increasing enrolment from the current 
dismal low proportion of some 2 to 5% of potentially eligible participants 66,67. Initiatives such as 
NCI-MATCH 47, Lung-MAP 48, and the Cancer Research UK Stratified Medicines Initiative and 
MATRIX National Lung Cancer Trial 68 (EudraCT: 2014-000814-73) have set the precedent but the 
real value to the patient and healthcare systems will be when this becomes commonplace and 
encompasses more portfolios of drug development companies to ensure broad availability of 
developmental (and on market) therapeutics. 
We have made advances, but mostly through altering development strategies to fit with established 
healthcare systems, and progress has been slow. Perhaps it is time to ask if health care systems 
are out of pace with the science and the development process and as a consequence impeding 
therapeutic development? Health care systems that can implement precision medicine would 
greatly facilitate therapeutic development, and accelerating progress will require the adjustment of 
these systems so that they are aligned and capable to test and deliver precision medicine without 
the need for costly overlaying clinical trial infrastructure. 
 
Summary 
In recent years our understanding of precision therapeutic development has evolved rapidly, and in 
some areas has progressed from concept to reality. The development of frameworks, platforms 
and processes involved are significantly enabling modern oncology drug development. A central 
component of this is innovative clinical trial designs that have facilitated the need to better appraise 
tumour biology, drug efficacy and patient benefit. New developmental paradigms are emerging, 
and driving new ways of working collaboratively to accelerate progress. In an evolving era of 
precision medicine, we have made significant early steps forward in generating truly patient-centric 
clinical trials and can claim that we are now often able to “select the trial for the patient”. However, 
significant hurdles remain and we need to establish broad frameworks and systems that integrate 
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closely with health care delivery to accelerate progress and realise the true promise of precision 
medicine. 
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A: Precision Medicine clinical trials 
Study	   Tumour/s	   Phase/Design	   Location	   Arms1	   Patients2	   Clinical	  Trial	  ID3	   Refs	  
Lung-­‐MAP	   Squamous	  lung	   Ph.2/3	  randomised	   USA	  
	  
	  
	  
	  
	  
	  
	  
	  
5	   10,000	   NCT02154490	   48	  
BATTLE	   NSCLC	   Umbrella	  –	  	  
route	  to	  4x	  Ph.2	  randomised	  
4	  
	  
300	   NCT00409968	  (umbrella);	  
NCT00411671	  NCT00411632	  
NCT00410059	  NCT00410189	  
30,69,7
0	  
BATTLE-­‐2	   NSCLC	   Ph.2	  randomised	   4	   450	   NCT01248247	   -­‐	  
BATTLE-­‐FL	   NSCLC	   Ph.2	  randomised	   4	   225	   NCT01263782	   -­‐	  
I-­‐SPY	  2	   Breast	  cancer	   Ph.2	  randomised	   8	   800	   NCT01042379	   71,72	  
NCI-­‐MPACT	   All	   Ph.2	  stratified,	  non-­‐randomised	   6	   700	   NCT01827384	   73	  
NCI-­‐MATCH	   Solids	   Ph.2	  stratified,	  non-­‐randomised	   20	   3,000	   Umbrella,	  route	  to	  Ph.24	   47	  
V-­‐BASKET	   All	   Ph.2	  stratified,	  non-­‐randomised	   Global	   2	   160	   NCT01524978	   74	  
CREATE	   Selected	   Ph.2	  stratified,	  non-­‐randomised	   EU	   6	   582	   NCT01524926	   -­‐	  
WINTHER	   All	   Stratified,	  non-­‐randomised	   2	   200	   NCT01856296	   75	  
SHIVA	   All	   Ph.2	  stratified,	  controlled	   France	   10	   1,000	   NCT01771458	   37	  
MOST	   All	   Ph.2	  stratified,	  randomised	  	   5	   560	   NCT02029001	   -­‐	  
SAFIR	  02	  Lung	  	   NSCLC	   Ph.2	  stratified,	  randomised	   8	   650	   NCT02117167	   76	  
SAFIR	  02	  Breast	   Breast	  cancer	   Ph.2	  stratified,	  randomised	   18	   460	   NCT02299999	   -­‐	  
Lung-­‐MATRIX	   NSCLC	   Ph.2	  stratified,	  non-­‐randomised	   UK	   215	   2,0006	   EudraCT:	  2014-­‐000814-­‐73	   68	  
FOCUS	  4	   Colorectal	  cancer	   Ph.2/3	  randomised	   4	   643	   EudraCT:	  2012-­‐005111-­‐12	   77	  
IMPaCT	   Pancreatic	  Cancer	   Ph.2	  stratified,	  randomised	   Australia	   4	   90	   ACTRN12612000777897	   46	  
B. Screening Programmes – feeders to precision medicine trials 
Study	   Tumour/s	   Phase/Design	   Location	   Diagnostics	   Patients2	   Clinical	  Trial	  ID	   Refs	  
I-­‐SPY	   Breast	  cancer	   Ph.2,	  diagnostic	  study	   US	   Genomic,	  imaging	   221	   NCT00043017	   31-­‐34	  
NCI-­‐MATCH	   Solids	   Screening,	  route	  to	  Ph.2	   NGS,	  (IHC/FISH)7	   3,000	   -­‐	   47	  
VIKTORY	   Gastric	  cancer	   Screening,	  route	  to	  Ph.2	   Asia	   NGS,	  other8	   600	   NCT02299648	   -­‐	  
LC-­‐SCRUM	   NSCLC	   Screening,	  route	  to	  Ph.2/3	   As	  needed9	   Open10	   -­‐	   52	  
AURORA	   Breast	  cancer	   Screening,	  route	  to	  Ph.1/2/3	   EU	   NGS,	  other11	   1,300	   NCT02102165	   51	  
SPECTAColor	  	   Colorectal	  cancer	   Screening,	  route	  to	  Ph.1/2/3	   NGS	   2,600	   NCT01723969	   49	  
SPECTALung	   Lung	   Screening,	  route	  to	  Ph.1/2/3	   NGS,	  other	   	   NCT02214134	   50	  
MOSCATO	   All	   Screening,	  route	  to	  Ph.1/2	   France	   CGH	  array,	  
	  sequencing	  
1,050	   NCT01566019	   20	  
SAFIR	  01	   Breast	  cancer	   Screening,	  route	  to	  Ph.1/2	   CGH,	  	  sequencing,	  	  
gene	  expression	  array	  
423	   NCT01414933	   76	  
CRUK	  SMP1	   Selected	   Screening,	  feasibility	   UK	   Bespoke	  panel	   9,000	   -­‐	   35	  
16	  
	  
 
Table 1: Precision medicine studies 
Selected examples of a) Precision Medicine clinical trials, and b) Screening Programmes acting as 
feeders to precision medicine clinical trials (including diagnostic and feasibility studies).  Clinical 
Trial ID - detailed information is available for each study via the ClinicalTrials.gov (NCT) or 
European Clinical Trials Register (EudraCT) identifier/number.  Ph., phase (clinical trial phase 1, 2 
or 3); NSCLC, non-small centre lung cancer; NGS, next generation sequencing; IHC, 
immunohistochemistry; FISH, fluorescent in-situ hybridisation; CGH, comparative genomic 
hybidisation.  1Arms – number of experimental arms included in the reported study design, specific 
details available via the ClinicalTrials.gov identifier; 2Estimated number of patients to be recruited, 
or final number recruited where the study has completed; 4The NCI-MATCH programme is a 
screening programme used to direct patients to single-arm, phase 2, signal seeking studies; 5The 
number of arms will vary as the study progresses, each arm designed around a marker (for patient 
selection) and (candidate) drug pair; 6screening 2,000 patients per annum once the study is fully 
operational; 7FISH and IHC assays will be used as required; 8other – a selection of bespoke and 
exploratory diagnostics; 9bespoke diagnostics as needed to select patients for the individual clinical 
studies that feed from the screening programme; 10an open and rolling programme; 11other – RNA 
sequencing (RNA-Seq). 
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1. Participant screening and recruitment in to trials 
 
Requires a viable means to identify low incidence 
subpopulations and direct individuals to an 
appropriate clinical trial, through a patient-centric 
approach whereby each individual can have 
access to many options via the one screening 
process 
 
• Region-wide and collaborative screening programs 
• Links to umbrella and basket studies 
• Links to global studies – with global studies able to 
accept participants from diverse screening routes 
• Drug portfolios available – via collaboration – and 
safeguards for proprietary information when using 
many partners portfolios 
• Harmonised and/or cross-validated multiplexed 
diagnostic platforms and systems – to allow 
recruitment irrespective of technology 
• Regulators open to change in how clinical trials 
need to be run 
• Networks, collaborations and good partners 
2. Molecular testing 
 
Requires a system (platform, screening/selection 
algorithm) that enables broad but robust 
tumour/patient profiling and provides viable 
development routes for larger/Global studies, 
regulatory interactions and support for markets 
 
• Platform 
• Screening/selection algorithm 
• Broad patient profiling 
• Sample efficient 
• Robust data generation 
• Cost-effective 
• Transferable, widely deployable 
• Works to agreed standards 
• Viable development route 
• Support regulatory interactions 
• Support for markets 
3. Protocol flexibility 
 
Requires an early development protocol that is 
flexible allowing change to emerging science and 
understanding of patients/tumour markers, and/or 
a confirmatory development protocol permitting 
regulatory interactions using different types of 
datasets 
 
• Single or aligned protocol 
• Aligned and efficient review – using a centralised 
Regulatory/Ethics process 
• Flexible 
• Modular 
• Rolling – open ended 
• Adaptable to emerging science 
• Allows different datasets to accumulate 
• Allows regulatory interactions 
4. Availability and delivery of therapies 
 
Requires an operational machinery that allows 
studies to be conducted over diverse groups and 
geographical areas with aligned and efficient 
regulatory and ethics processes, patient 
screening/recruitment and ability to distribute 
multiple candidate drugs to multiple sites in  a 
cost-effective and efficient manner 
 
• Hub-and-spoke models 
• Must accommodate diverse groups and 
geographical areas 
• Centralised Pharmacy – to enable cost-effective 
delivery of multiple drugs to multiple sites 
• Highly collaborative working – across many 
different groups 
• Good partners 
 
Table 2: Successful delivery of multidrug portfolio studies requires innovation across clinical trial 
design and implementation; key aspects to consider for diagnostics, clinical protocol and 
operational delivery. 
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Figure 1: RCT and Biomarker Driven Designs 
 
 
 
Randomised clinical trial (RCT) designs to define and test precision medicine strategies: a) 
Biomarker discovery and development within a trial addressing a therapeutic question and patient 
recruitment or treatment allocation not informed by biomarker status, b) Non-targeted biomarker 
study where the trial is designed and powered to addres the biomarker hypothesis to ensure 
adequate biomarker representation and distribution between arms, c) Biomarker targeted RCT 
where the presence of the selection marker guides recruitment, and d) where the overall concept 
of the approach can be tested as a whole when biomarker directed therapy is compared to 
conventional therapy (adapted from Chee et al.). 
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Figure 2 
 
 
Clinical trial principles that generate efficiencies in clinical trials that tested targeted 
therapies: a: Umbrella study design – where patients with the same cancer type are assayed for 
a series of hypothesised predictive markers and allocated to appropriate therapies within the trial 
architecture. b:	  Basket	  study	  design	  –	  where	  participants	  are	  recruited	  based	  on	  molecular	  characteristics	  
irrespective	  of	  the	  organ	  of	  origin. c: Prevalence maps of molecular subtypes within and across 
cancer types: The relative incidence of molecular subtypes can help guide decisions as to which 
clinical trial strategy may be most appropriate when deciding between an “umbrella” or a “basket 
approach. Left: Molecular subtypes when classified by organ of origin and stratified by molecular 
subtype. Right: A “biotype” classification based on molecular subtyping and stratified  by organ of 
origin may be more appropriate operationally when the incidence of a specific molecular class is 
low across different organs of origin and tested with a “basket” approach. (Adapted from ref 76 78). 
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Figure	  3	  
	  
	  
	  
	  
	  
Adaptive study designs - a within study analysis or continual assessment of data is used to 
change the study course; for example, to stop trial arms on lack of clinical benefit, to extend trial 
arms to increase numbers for further analysis, or to redefine subpopulations based on 
responder/non-responder analysis. 
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Figure 4 
 
 
Master protocols for therapeutic development: Example of an overarching schema for 
clinical testing of precision oncology strategies. The overriding principle is that all patients that 
are suitable for treatment are offered a choice of therapies, from biomarker directed or unselected 
novel therapeutic strategies either as part of the structure or for external trials; through to standard 
of care, where they are still tracked to inform biomarker discovery opportunities for existing 
approved therapeutics. The strategy could be enacted either under the auspices of a single body 
or more pragmatically a composite or network of organisations and activities through an agreed co-
ordinated management and governance structure. The framework is enacted in 2 stages. Stage 1 
includes patient recruitment and molecular testing. Participants can enter either pretested or 
directed to molecular testing wither within, or by external providers. A series of attractive options 
are available for patients and clinicians to choose from with a second stage consent process for 
trials. 
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Figure 5 
 
Early stratified therapeutic development. A key element is the strategy for early therapeutic 
development are small trials underpinned by a deep understanding of patient and tumour 
molecular pathology in order to guide on-going development. A step-wise development approach is 
used with interim analyses, expansion and molecular assessment at specific points. PR: Partial 
Response based on RECIST 1.0 criteria 79. 
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Figure 6 
 
 
 
 
Clinical Testing Strategies. A significant challenge in testing stratified therapeutic strategies is 
approaching lower prevalence segments and the level of evidence acceptable to embark on later 
phase studies. This matrix shows a potential overall approach, which is a function of the existing 
level of evidence, the feasibility of the testing strategy (prevalence of segment) and regulatory 
requirements. Trials may also progress as the level of evidence increases, and this progression 
may be built into planned step-wise development process. 
 
